ANX-005 is a Monoclonal Antibody owned by Annexon, and is involved in 9 clinical trials, of which 3 were completed, 5 are ongoing, and 1 is planned.

ANX-005 inhibits early components of the classical complement cascade. C1q, the initiating protein of the classical cascade, regulates the elimination of nerve connections. In a number of neurological disorders, C1q interacts with nerve components to activate the classical complement cascade which causes significant damage to nerves and nerve connection.

The revenue for ANX-005 is expected to reach a total of $846m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ANX-005 NPV Report.

ANX-005 was originated by Stanford University and is currently owned by Annexon.

ANX-005 Overview

ANX-005 is under development for the treatment and acute antibody-mediated autoimmune disease such as Guillain-Barre syndrome, amyotrophic lateral sclerosis, warm autoimmune hemolytic anemia, Huntington disease and multifocal motor neuropathy (MMN). It is administered as intravenous infusion. The drug candidate is a humanized monoclonal antibody that inhibits early components of the classical complement cascade. It is based on composite human antibody technology. The drug candidate was also under development for the treatment of Alzheimer's disease.

Annexon Overview

Annexon is a developer of therapeutic products and pathway inhibitors for the treatment of neurological disorders. The company develops treatments for Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration. Its lead drug candidates include ANX005 and ANX007, which are potent inhibitory antibodies against C1q, an initiating molecule of the classical complement cascade. The compay also develops ANX105, for the treatment of neurodegenerative disorders. It develops therapeutic products to protect against synapse loss and inflammatory nerve damage in brain and retinal cells. Annexon is headquartered in South San Francisco, California, the US.

The operating loss of the company was US$130.7 million in FY2021, compared to an operating loss of US$63.5 million in FY2020. The net loss of the company was US$130.3 million in FY2021, compared to a net loss of US$63.4 million in FY2020.

Quick View – ANX-005

Report Segments
  • Innovator
Drug Name
  • ANX-005
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.